Joshua Gustine Selected Research

Waldenstrom Macroglobulinemia (Macroglobulinemia)

1/2021	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
1/2018	MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
1/2018	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
1/2018	BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
5/2017	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
1/2017	Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joshua Gustine Research Topics

Disease

6	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2021 - 01/2017
3	Lymphoma (Lymphomas) 01/2022 - 11/2016
2	Bone Marrow Diseases (Bone Marrow Disease) 01/2021 - 05/2017
2	Disease Progression 01/2018 - 01/2017
2	Neoplasms (Cancer) 01/2018 - 01/2018
1	Immunoglobulin Light-chain Amyloidosis 01/2022
1	Cardiac Arrhythmias (Arrythmia) 01/2021
1	Multiple Myeloma 01/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018
1	Thrombotic Microangiopathies 11/2016
1	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 11/2016
1	Amyloidosis 11/2016
1	Membranous Glomerulonephritis (Membranous Nephropathy) 11/2016

Drug/Important Bio-Agent (IBA)

5	ibrutinibIBA 01/2021 - 01/2017
4	Immunoglobulin M (IgM)IBA 01/2021 - 11/2016
2	Hemoglobins (Hemoglobin)IBA 01/2021 - 05/2017
1	pro-brain natriuretic peptide (1-76)IBA 01/2022
1	A 419259IBA 01/2022
1	daratumumabIBA 01/2022
1	src-Family KinasesIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	Interleukin-10 (Interleukin 10)IBA 01/2018
1	Everolimus FDA Link 05/2017

Therapy/Procedure

3	Therapeutics 01/2022 - 05/2017
1	Duration of Therapy 01/2022
1	Drug Therapy (Chemotherapy) 01/2022